Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: July 2008
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Endo Pharmaceuticals Inc. et al. v. Actavis South Atlantic LLC2:08-cv-03482; filed July 11, 2008 in the District Court of New Jersey Infringement…
-
July 24-25, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – New York, NY August 11-12, 2008 – Advanced Patent Prosecution Workshop 2008: Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco, CA August 10-15, 2008 – Advanced Courses (Patent Resources Group) – Washington, DC September…
-
C5 (UK) will be holding its Pharma/Biotech IP Due Diligence conference on October 28-29, 2008 in Amsterdam, Netherlands. The conference will offer presentations on the following topics: • Current trends in patent reform and how they impact your due diligence;• Assessing the level of due diligence required and special considerations for complex multi-jurisdictional and multi-party…
-
By Kevin E. Noonan — The Federal Circuit clarified its position on method claim infringement to the detriment of the plaintiff in Muniauction, Inc. v. Thomson Corp., vacating an $84.6 million dollar judgment (in a contingency fee case, no less). In a jury trial, Defendants Thomson Corp. and I-Deal LLC were found to…
-
By Donald Zuhn — Insmed Inc., a biopharmaceutical company based in Richmond, Virginia, announced today that it has retained the former Chairman of the House Ways and Means Committee, Bill Thomas (at right), as a strategic advisor in its continuing effort "to bring follow-on biologics to U.S. customers and consumers." The former Representative…
-
By Donald Zuhn — The U.S. Patent and Trademark Office today released a summary of the feedback it received in response to its April 30, 2008 webcast concerning user access to the Public Patent Application Information Retrieval (PAIR) system. During the webcast, Commissioner for Patents John Doll and Deputy Chief Information Officer Deborah…
-
By Kevin E. Noonan — Federal Circuit jurisprudence on whether an Article III case or controversy exists continues to evolve regarding the extent to which federal district courts can exercise jurisdiction in patent cases, most recently in Merck & Co. v. Apotex, Inc. (nonprecedential). The dispute was over Apotex’s ANDA filing for a…
-
By Sherri Oslick — Earlier this month by consent judgment, the Paragraph IV litigation between Eli Lilly and Glenmark Pharmaceuticals over Lilly’s ADHD drug Strattera® was terminated. Per the parties’ stipulation, Glenmark agreed that the patent-in-suit was neither invalid nor unenforceable, and further agreed to a permanent injunction enjoining it from manufacturing or…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that it was initiating a pilot program to promote worksharing between the USPTO, European Patent Office, and Japan Patent Office. The pilot program, dubbed "Triway," was first proposed by the USPTO at the 2005 Trilateral Pre-conference; the Trilateral Offices agreed at…
-
By Donald Zuhn — In an op-ed piece in today’s Wall Street Journal, L. Gordon Crovitz opines that Congress’ failure to enact patent reform this year has undermined the Constitutional mandate to encourage innovation (see "Patent Gridlock Suppresses Innovation"). The fault for our flawed system, according to Mr. Crovitz, rests with Congress, which…
Patent Docs 